BACKGROUND: The liver is a major organ that is susceptible to injury after blunt or penetrating trauma to the abdomen. No specific nonoperative treatment exists for traumatic hepatic injury (THI). Adrenomedullin (AM), a vasoactive peptide, combined with its binding protein, AM protein (AMBP-1), is beneficial in various disease conditions. In this study, we propose to analyze whether human AM combined with human AMBP-1 provides benefit in a model of THI in the rat. METHODS: Male adult rats were subjected to trauma hemorrhage by resection of ∼50% of total liver tissues and allowed bleeding for 15 minutes. Immediately thereafter, human AM (48 μg/kg birth weight) plus human AMBP-1 (160 μg/kg birth weight) were given intravenously over 30 minutes in 1-mL normal saline. After 4 hours, the rats were killed, blood was collected, and tissue injury indicators were assessed. A 10-day survival study was also conducted. RESULTS: At 4 hours after THI, plasma AMBP-1 levels were markedly decreased. Plasma levels of liver injury indicators (i.e., aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase) were significantly increased after THI. Similarly, lactate, creatinine, and tumor necrosis factor-α levels were significantly increased after THI. Administration of human AM/AMBP-1 after THI produced significant decreases of 64%, 23%, and 19% of plasma aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase levels, respectively. Similarly, plasma levels of lactate, creatinine, and tumor necrosis factor-α were also decreased by 42%, 28%, and 46% after human AM/AMBP-1 treatment, respectively. In a 10-day survival study, although vehicle treatment produced 41% survival, human AM/AMBP-1 treatment improved the survival rate to 81%. CONCLUSIONS: Administration of human AM/AMBP-1 significantly attenuated tissue injury and inflammation and improved survival after THI. Thus, human AM/AMBP-1 can be developed as a novel treatment for victims with uncontrolled traumatic hemorrhage.
BACKGROUND: The liver is a major organ that is susceptible to injury after blunt or penetrating trauma to the abdomen. No specific nonoperative treatment exists for traumatic hepatic injury (THI). Adrenomedullin (AM), a vasoactive peptide, combined with its binding protein, AM protein (AMBP-1), is beneficial in various disease conditions. In this study, we propose to analyze whether humanAM combined with humanAMBP-1 provides benefit in a model of THI in the rat. METHODS: Male adult rats were subjected to trauma hemorrhage by resection of ∼50% of total liver tissues and allowed bleeding for 15 minutes. Immediately thereafter, humanAM (48 μg/kg birth weight) plus humanAMBP-1 (160 μg/kg birth weight) were given intravenously over 30 minutes in 1-mL normal saline. After 4 hours, the rats were killed, blood was collected, and tissue injury indicators were assessed. A 10-day survival study was also conducted. RESULTS: At 4 hours after THI, plasma AMBP-1 levels were markedly decreased. Plasma levels of liver injury indicators (i.e., aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase) were significantly increased after THI. Similarly, lactate, creatinine, and tumor necrosis factor-α levels were significantly increased after THI. Administration of humanAM/AMBP-1 after THI produced significant decreases of 64%, 23%, and 19% of plasma aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase levels, respectively. Similarly, plasma levels of lactate, creatinine, and tumor necrosis factor-α were also decreased by 42%, 28%, and 46% after humanAM/AMBP-1 treatment, respectively. In a 10-day survival study, although vehicle treatment produced 41% survival, humanAM/AMBP-1 treatment improved the survival rate to 81%. CONCLUSIONS: Administration of humanAM/AMBP-1 significantly attenuated tissue injury and inflammation and improved survival after THI. Thus, humanAM/AMBP-1 can be developed as a novel treatment for victims with uncontrolled traumatic hemorrhage.
Authors: Alicia M Mohr; Robert F Lavery; Allison Barone; Philip Bahramipour; Louis J Magnotti; Adena J Osband; Ziad Sifri; David H Livingston Journal: J Trauma Date: 2003-12
Authors: Alfredo Martínez; Hae-Ryong Oh; Edward J Unsworth; Claudia Bregonzio; Juan M Saavedra; William G Stetler-Stevenson; Frank Cuttitta Journal: Biochem J Date: 2004-11-01 Impact factor: 3.857
Authors: Iosifina I Karmaniolou; Kassiani A Theodoraki; Nikolaos F Orfanos; Georgia G Kostopanagiotou; Vasileios E Smyrniotis; Anastasios I Mylonas; Nikolaos F Arkadopoulos Journal: J Anesth Date: 2012-12-29 Impact factor: 2.078
Authors: Nathan Egge; Sonja L B Arneaud; Rene Solano Fonseca; Kielen R Zuurbier; Jacob McClendon; Peter M Douglas Journal: Nat Commun Date: 2021-03-05 Impact factor: 14.919